Literature DB >> 30821505

Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease.

Seyedeh Zahra Badrkhahan1, Hajir Sikaroodi2, Farshad Sharifi3,4, Leila Kouti5, Maryam Noroozian6.   

Abstract

Parkinson's disease (PD) is a progressive multifactorial degenerative disorder that has both motor and nonmotor features. Among the nonmotor features of PD, cognitive impairment; Mild Cognitive Impairment (MCI) and dementia, poses one of the most significant implications for disability. Because of the high possibility of developing Dementia in PD, it is essential to obtain a reliable cognitive screen. Two commonly used cognitive measures include the Mini Mental Status Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). The MoCA is a more sensitive tool for the detection of MCI in compared to the MMSE. Because of the cultural differences, in this study, we evaluated the psychometric properties of the Persian version of the MoCA (MoCA-P) in a group of participants with PD in Iran. Participants were assessed by MMSE, Geriatric Depression Scale (GDS), and Functional Assessment Staging Test (FAST). If they met study eligibility, the MoCA-P scale was administered. Receiver Operating Characteristic (ROC) curve analyses showed that the MoCA-P scale produced significant discrimination of PD with Dementia (PDD) from PD with MCI (PD-MCI). It seems that the MoCA-P has adequate psychometric properties as a screening instrument for the detection of PD-MCI and PDD in Iranian patients. As near to 30% of patients with PD go on to develop dementia, the MoCA-P can be useful in the detection of cognitive impairment in patients with PD and is suitable for executive function assessment.

Entities:  

Keywords:  Elderly; MoCA; Montreal Cognitive Assessment; Parkinson disease dementia; Parkinson’s disease; older adults; reliability; validity

Mesh:

Year:  2019        PMID: 30821505     DOI: 10.1080/23279095.2019.1565762

Source DB:  PubMed          Journal:  Appl Neuropsychol Adult        ISSN: 2327-9095            Impact factor:   2.248


  7 in total

1.  How do cannabis users mentally travel in time? Evidence from an fMRI study of episodic future thinking.

Authors:  Parnian Rafei; Tara Rezapour; Seyed Amir Hossein Batouli; Antonio Verdejo-García; Valentina Lorenzetti; Javad Hatami
Journal:  Psychopharmacology (Berl)       Date:  2021-10-25       Impact factor: 4.530

2.  Prevalence of mild behavioral impairment in patients with mild cognitive impairment.

Authors:  Gilda Kianimehr; Farzad Fatehi; Maryam Noroozian
Journal:  Acta Neurol Belg       Date:  2021-06-30       Impact factor: 2.396

3.  Multiculturalism: A Challenge for Cognitive Screeners in Parkinson's Disease.

Authors:  Marta Statucka; Kirsten Cherian; Alfonso Fasano; Renato P Munhoz; Melanie Cohn
Journal:  Mov Disord Clin Pract       Date:  2021-05-27

4.  Psychometric Properties of the Persian Montreal Cognitive Assessment in Mild Cognitive Impairment and Alzheimer Disease.

Authors:  Vahid Rashedi; Mahshid Foroughan; Negin Chehrehnegar
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2021-03-19

5.  A systematic review and meta-analysis of studies on screening for mild cognitive impairment in primary healthcare.

Authors:  Leila Karimi; Alireza Mahboub-Ahari; Leila Jahangiry; Homayoun Sadeghi-Bazargani; Mostafa Farahbakhsh
Journal:  BMC Psychiatry       Date:  2022-02-09       Impact factor: 3.630

6.  A New Instrument Combines Cognitive and Social Functioning Items for Detecting Mild Cognitive Impairment and Dementia in Parkinson's Disease.

Authors:  Ya-Wen Yu; Chun-Hsiang Tan; Hui-Chen Su; Chung-Yao Chien; Pi-Shan Sung; Tien-Yu Lin; Tsung-Lin Lee; Rwei-Ling Yu
Journal:  Front Aging Neurosci       Date:  2022-06-16       Impact factor: 5.702

7.  Early Detection of Radiation-Induced Injury and Prediction of Cognitive Deficit by MRS Metabolites in Radiotherapy of Low-Grade Glioma.

Authors:  Zahra Alirezaei; Alireza Amouheidari; Masoud Hassanpour; Fariba Davanian; Sajjad Iraji; Parvaneh Shokrani; Mohammad-Reza Nazem-Zadeh
Journal:  Biomed Res Int       Date:  2021-03-04       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.